Bausch Advances Novel Dry Eye Therapeutic to Phase 3

Quebec based B+L has announced the second of two Phase 3 studies studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a first-in- class investigational drug to treat the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).

According to the company, the new proprietary compound NOV03 is a proprietary, water-free and preservative-free solution, based on patented EyeSol® technology from German company, Novaliq GmbH. The drug has a novel mechanism of action to treat Dry Eye Disease associated with MGD.

NOV03 showed statistically significant improvement of certain symptoms, such as severity and frequency of dryness and burning/stinging of the eyes, over the entire duration of the Phase 2 study (336 patients) with no notable safety events.

View the full Press Release from B+L

Featured Posts

CooperVision Appoints Alex Wilkes as President, Americas

CooperVision has named Alex Wilkes as President, Americas, effective June 14. Wilkes brings more than a decade of experience in the eye care industry, having most recently served as Senior Vice President and General Manager of Pearle Vision at Luxottica.

Learn More

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

Read more

Lanvin Unveils New Mother and Child Sunglasses

These feminine sunglasses are designed in an oversized rectangular silhouette, crafted in lightweight acetate.

Read more

A Successful First Half Year for ZEISS

The positive trend continues at the ZEISS Group, which had a positive end to the first six months of fiscal year 2021/22 (ended 31 March 2022) that was significantly higher than the very good result seen in the previous year.

Read more

SILMO Paris 2022: Return to Normalcy

After the successful 2021 reunion, the upcoming edition heralds a return to normalcy and the much-awaited SILMO Paris.

Read more

CooperVision Appoints Alex Wilkes as President, Americas

CooperVision has named Alex Wilkes as President, Americas, effective June 14. Wilkes brings more than a decade of experience in the eye care industry, having most recently served as Senior Vice President and General Manager of Pearle Vision at Luxottica.

Learn More

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

Read More

Lanvin Unveils New Mother and Child Sunglasses

These feminine sunglasses are designed in an oversized rectangular silhouette, crafted in lightweight acetate.

Read More

A Successful First Half Year for ZEISS

The positive trend continues at the ZEISS Group, which had a positive end to the first six months of fiscal year 2021/22 (ended 31 March 2022) that was significantly higher than the very good result seen in the previous year.

Read More

SILMO Paris 2022: Return to Normalcy

After the successful 2021 reunion, the upcoming edition heralds a return to normalcy and the much-awaited SILMO Paris.

Read More

CooperVision Appoints Alex Wilkes as President, Americas

CooperVision has named Alex Wilkes as President, Americas, effective June 14. Wilkes brings more than a decade of experience in the eye care industry, having most recently served as Senior Vice President and General Manager of Pearle Vision at Luxottica.

Learn More

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

Read more

Lanvin Unveils New Mother and Child Sunglasses

These feminine sunglasses are designed in an oversized rectangular silhouette, crafted in lightweight acetate.

Read more

A Successful First Half Year for ZEISS

The positive trend continues at the ZEISS Group, which had a positive end to the first six months of fiscal year 2021/22 (ended 31 March 2022) that was significantly higher than the very good result seen in the previous year.

Read more

SILMO Paris 2022: Return to Normalcy

After the successful 2021 reunion, the upcoming edition heralds a return to normalcy and the much-awaited SILMO Paris.

Read more

CooperVision Appoints Alex Wilkes as President, Americas

CooperVision has named Alex Wilkes as President, Americas, effective June 14. Wilkes brings more than a decade of experience in the eye care industry, having most recently served as Senior Vice President and General Manager of Pearle Vision at Luxottica.

Learn More

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

Read more

Lanvin Unveils New Mother and Child Sunglasses

These feminine sunglasses are designed in an oversized rectangular silhouette, crafted in lightweight acetate.

Read more

A Successful First Half Year for ZEISS

The positive trend continues at the ZEISS Group, which had a positive end to the first six months of fiscal year 2021/22 (ended 31 March 2022) that was significantly higher than the very good result seen in the previous year.

Read more

SILMO Paris 2022: Return to Normalcy

After the successful 2021 reunion, the upcoming edition heralds a return to normalcy and the much-awaited SILMO Paris.

Read more